Blocking the MIF cytokine family to improve cancer therapy

Research output: Unpublished contribution to conferencePoster


Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine, that upon binding to its main receptor, CD74, promotes angiogenesis, cell survival, and the expression of pro-inflammatory cytokines. This cytokine has been recognized as a biomarker of different autoimmune and cardiovascular diseases, metabolic disorders, systemic infections, and several types of cancer. The blockade of MIF by small synthetic compounds (ISO-1; ISO-66), or its genetic ablation in several cancer models resulted in a significant tumor reduction, confirming its pro-tumoral role. In this regard, our laboratory has identified anti-mouse/human MIF cross-reactive nanobodies (Nbs, i.e. recombinant variable domains of heavy-chain-only antibodies), that were able to prevent endotoxic shock in an experimental murine model. In addition, when used as a monotherapy, these anti-MIF Nbs significantly reduced the MC-38 colorectal cancer tumor growth by promoting an anti-tumoral immune response. Additionally, when combined with anti-PD-1 treatment, a superior tumor regression was observed compared to the use of anti-PD-1 monotherapy alone.
Finally, the tailorability of the Nbs could also facilitate the design of multivalent Nb constructs directed against MIF.
Original languageEnglish
Publication statusPublished - 19 Sep 2023
EventThe Single-Domain Antibodies 2023 meeting: 3rd congress on single-domain antibodies - CIS auditorium, Institut Pasteur, Paris, France
Duration: 18 Sep 202320 Sep 2023


ConferenceThe Single-Domain Antibodies 2023 meeting
Internet address

Cite this